Clinical trial
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza…
NCT00363077 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00363077 |
|---|---|
| Title | Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate |
| Official title | A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | GSK1247446A Group, Fluarix™ |
| Enrollment | 150 |
| Start date | Oct 2, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 17, 2006 |
| First posted | Aug 15, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: